Pernicious Anemia Clinical Trial
Official title:
Megadose of Hydroxocobalamin (Vitamin B12) for the Treatment of Pernicious Anemia
Verified date | March 2021 |
Source | Hospital Universitario Dr. Jose E. Gonzalez |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Demonstrate the effectiveness of a single dose of a multivitamin complex for the treatment of megaloblastic anemia
Status | Completed |
Enrollment | 13 |
Est. completion date | December 1, 2019 |
Est. primary completion date | December 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: Age >18, All sex Clinical suspicious of megaloblastic anemia ( cytopenias and macrocytosis (CBC), hypersegmented neutrophils and elevated lactate dehydrogenase) Patients must sign an informed consent indicating that they are aware of the investigational nature of this study - Exclusion Criteria: Administration of hydroxocobalamin in the three years before enrollment Patients with active, uncontrolled psychiatric disorders Severe neurologic deficit Known hematologic malignancy Known coagulation disorder that contraindicates intramuscular injection End-stage kidney disease (GFR <15ml/min) Chronic liver disease (Child-Pugh B or C) Pregnant patients Known infection of Hepatitis B or C and HIV Diagnosis of myelodysplastic syndrome - |
Country | Name | City | State |
---|---|---|---|
Mexico | Hospital Universitario Dr. Jose E Gonzalez UANL | Monterrey | Nuevo Leon |
Lead Sponsor | Collaborator |
---|---|
Hospital Universitario Dr. Jose E. Gonzalez |
Mexico,
Green R. Vitamin B(12) deficiency from the perspective of a practicing hematologist. Blood. 2017 May 11;129(19):2603-2611. doi: 10.1182/blood-2016-10-569186. Epub 2017 Mar 30. Review. — View Citation
Sanz-Cuesta T, González-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-González I, Martín-Fernández J, Escortell-Mayor E, Rodríguez-Salvanés F, García-Solano M, González-González R, Martín-de la Sierra-San Agustín MÁ, Olmedo-Lucerón C, Sevilla — View Citation
Sharabi A, Cohen E, Sulkes J, Garty M. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route. Br J Clin Pharmacol. 2003 Dec;56(6):635-8. — View Citation
Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013 May 23;368(21):2041-2. doi: 10.1056/NEJMc1304350. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hematologic response | Normalization of complete blood count (CBC). | 2 month | |
Primary | Duration of hematologic response | Duration of response (months) after the administration of megadose of hydroxocobalamin | 6 months | |
Secondary | Measure levels of hydroxocobalamin | Basal, three and six months | ||
Secondary | Measure levels of methylmalonic acid. | Basal, three and six months | ||
Secondary | Measure levels of homocysteine. | Basal, three and six months | ||
Secondary | Evaluate time to hematologic response | Time to response after the administration of 10,000mcg hydroxocobalamin | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT03941184 -
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
|